Low protein s in essential thrombocythemia with thrombosis
β Scribed by MD Maureen G. Conlan; William D. Haire
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 564 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Recent advances permit the detection of activated piatelets using specific monoclonal antibodies and flow cytometry. Nevertheless, there are few reports in which activated platelets have been studied over a period of time in patients at risk for thrombosis. Our patient S.D. has essential thrombocyth
The aim of this study was to investigate whether abnormalities in the fibrinolytic system and in the naturally occurring anticoagulant proteins could contribute to the thrombotic risk in essential thrombocythemia. Euglobulin lysis time, fibrin plate lysis area, tissue plasminogen activator antigen,
## Abstract ## BACKGROUND There is currently insufficient evidence to either support or refute an association between estrogenβbased hormone treatment (EBHT) and thrombosis risk in essential thrombocythemia (ET). ## METHODS A retrospective review of thrombotic events, which occurred both at diag
We describe a case of essential thrombocythemia in a 34-year-old male who presented with acute anterior wall myocardial infarction and a platelet count of 2,100,000/mm 3 . Primary percutaneous coronary angioplasty and stenting were performed. Postangioplasty course was complicated by stent thrombosi